Hagens Berman Reminds Investors in Aceto Corporation (ACET)

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
87
Hagens Berman Reminds Investors in Aceto Corporation (ACET) of the June 25, 2018 Securities Class Action Lead Plaintiff Deadline

SAN FRANCISCO, June 18, 2018 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Aceto Corporation (NASDAQ: ACET ) of the June 25, 2018 securities class action Lead Plaintiff deadline.  If you purchased or otherwise acquired Aceto securities between August 25, 2017 and April 18, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP.  For more information visit:

https://www.hbsslaw.com/cases/ACET

or contact Reed Kathrein, who is leading the firm’s investigation, by calling 510-725-3000 or emailing

ACET@hbsslaw.com .

On April 18, 2018, Defendants announced (1) their financial guidance issued on February 1, 2018 should no longer be relied upon, (2) Aceto anticipates recording asset impairment charges in the range of $230 million to $260 million on certain currently marketed and pipeline generic products, and (3) Aceto’s Chief Financial Officer (Edward Borkowski) resigned after just two months in that position.

This news drove the price of Aceto shares down $4.74, or over 64%, to close at $2.66 that day.

“We’re focused on investors’ losses and whether Aceto and senior officers knowingly violated Generally Accepted Accounting Principles,” said Hagens Berman partner Reed Kathrein.

Whistleblowers:   Persons with non-public information regarding Aceto should consider their options to help in the investigation or take advantage of the SEC Whistleblower program.  Under the new program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC.  For more information, call Reed Kathrein at 510-725-3000 or email ACET@hbsslaw.com .

About Hagens Berman Hagens Berman is a national investor-rights law firm headquartered in Seattle, Washington with 70+ attorneys in 11 offices across the country.  The Firm represents investors, whistleblowers, workers and consumers in complex litigation.  More about the firm and its successes can be found at www.hbsslaw.com .  For the latest news visit our newsroom or follow us on Twitter at @classactionlaw .

Contact: Reed Kathrein, 510-725-3000

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Halozyme's Upcoming Investment Presentation at Healthcare Conference

Updated Category News Views 280

Halozyme's Participation in Major Healthcare Conference Halozyme Therapeutics, Inc. (NASDAQ: HALO) is set to showcase its advancements at an important healthcare conference. Dr. Helen Torley, the president and CEO, will present and engage in investor meetings, highlighting the company's innovative approaches in the biopharmaceutical sector. Details of the Presentation The...

Continue Reading
Emerging Markets Surge Ahead with Historic Bond Sales Strategy

Updated Category News Views 241

Emerging Markets Adjust with Record Bond Sales Amid economic uncertainty, borrowers in developing regions are intensifying their efforts to navigate potential market turbulence, particularly due to significant fluctuations influenced by US economic conditions. Authorities and businesses have proactively begun securing funds through bond sales, reflecting a strategic move...

Continue Reading
Multi Ways Holdings Reflects on Fiscal Year 2024 Performance

Updated Category News Views 167

Multi Ways Holdings Limited Reports on Financial Results Multi Ways Holdings Limited (NYSE American: MWG), a prominent provider of heavy construction equipment, has recently shared its financial outcomes for the fiscal year 2024. With a focus on innovation and customer satisfaction in Singapore and neighboring regions, the company continues to adapt to the dynamic market...

Continue Reading
Neurocrine Adjusts Course Following Luvadaxistat Study Setback

Updated Category News Views 117

Neurocrine Biosciences Shifts Strategy After Luvadaxistat Trial Neurocrine Biosciences Inc. (NASDAQ: NBIX) has made revisions to its strategic approach following the outcomes of the ERUDITE phase two clinical trial involving luvadaxistat (NBI-1065844). This investigational treatment aimed at addressing cognitive impairment in schizophrenia did not achieve its primary...

Continue Reading
Rinnai America Leads Coalition Against DOE Water Heater Rule

Updated Category News Views 294

Rinnai America Takes Action Against DOE Regulations Rinnai America Corporation, a prominent manufacturer of noncondensing tankless water heaters, has joined forces with 21 state attorneys general and various business groups to challenge the recent final rule issued by the U.S. Department of Energy (DOE) concerning consumer tankless water heaters. This action follows a...

Continue Reading